NCT06514794 2026-04-22
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Phase 2 Recruiting
Clinical Trials
328 trialsNCT04067336 2026-04-21
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1/2 Recruiting
NCT04094311 2026-04-20
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT03960840 2026-04-17
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT03934372 2026-04-16
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
Phase 1/2 Recruiting
NCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT04811560 2026-04-14
cAMeLot-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07295951 2026-04-13
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05473910 2026-04-08
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
Phase 1 Recruiting
NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
NCT07109219 2026-04-06
ALLight
AstraZeneca
Phase 1/2 Recruiting
NCT03156790 2026-03-30
PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia
medac GmbH
Phase 2 Terminated
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT05748171 2026-03-20
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT04065399 2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2 Recruiting
NCT04635384 2026-03-18
ACROBAT
CareDx
Active not recruiting
NCT07155226 2026-03-18
MOMENTUM
AstraZeneca
Phase 1/2 Recruiting
NCT05397496 2026-03-17
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Novartis
Phase 1 Active not recruiting
NCT05316701 2026-03-04
Orca-T
Orca Biosystems, Inc.
Phase 3 Active not recruiting
NCT07223190 2026-03-04
AUDAX
Amgen
Phase 3 Not yet recruiting
NCT06173518 2026-03-02
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Phase 1 Recruiting
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT05255601 2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2 Completed
NCT06052813 2026-02-25
A Study of BN104 in the Treatment of Acute Leukemia
Servier
Phase 1/2 Active not recruiting
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05589896 2026-02-24
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
Phase 1/2 Recruiting
NCT03802695 2026-02-23
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Phase 1 Recruiting
NCT04817761 2026-02-18
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Servier
Phase 2/3 Terminated
NCT05579132 2026-02-13
MK-1045-002
MSD R&D (China) Co., Ltd.
Phase 1/2 Recruiting
NCT07070219 2026-02-05
TENACITY-01
BIOHENG THERAPEUTICS US LLC
Phase 1/2 Recruiting
NCT06539338 2026-02-04
INVISE
Gilead Sciences
Phase 1 Recruiting
NCT06578351 2026-02-04
TRAM
Danone Asia Pacific Holdings Pte, Ltd.
Completed
NCT07387926 2026-02-04
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1/2 Not yet recruiting
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT04139434 2026-01-23
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
Phase 1 Completed
NCT07346105 2026-01-16
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Orca Biosystems, Inc.
Temporarily not available
NCT04872478 2026-01-08
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Meryx, Inc.
Phase 1 Recruiting
NCT07312630 2025-12-31
Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07284927 2025-12-16
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT05086315 2025-12-15
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sanofi
Phase 1/2 Terminated
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05923112 2025-12-05
BESPONSA Injection 1 mg Special Investigation
Pfizer
Completed
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT06508775 2025-11-26
LONGSAFE
Miltenyi Biomedicine GmbH
Phase NA Recruiting
NCT04260022 2025-11-05
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT04984356 2025-09-30
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
Wugen, Inc.
Phase 1 Completed
NCT04606433 2025-09-26
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT06037018 2025-09-22
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
CytoCares Inc
Phase 1 Recruiting